tedisamil experimental class iii antiarrhythmic agent currently investigated treatment atrial fibrillation tedisamil blocks multiple types potassium channels heart resulting slowed heart rate effects tedisamil demonstrated atrial ventricular muscle repolarization prolonged efficiently tedisamil administered intravenously halflife approximately hours tedisamil developed alternative antiarrhythmics incidence additional arrhythmic events lower compared class iii tedisamil also significant antiischemic properties initially investigated potential treatment angina antiarrhythmic effects tedisamil manufactured solvay pharmaceuticals inc proposed trade name arrhythmias broadly defined abnormal electrical activity heart affect atria ventricles atrial arrhythmias common type arrhythmia several subtypes currently described including atrial fibrillation atrial fibrillation continual quivering atria contraction muscle normal conditions electrical impulse sinoatrial sa node distributed rapidly throughout atria causing coordinated excitement inactivation atrial muscle cell ion channels resulting uniform contraction relaxation muscle fibrillation electrical signals overwhelm sa node ion channel excitement longer uniform throughout results inappropriate activation properties preventing uniform contraction relaxation subsequent action potentials sa node able uniformly excite muscle channels available open still held inactivation results disjointed contraction quivering seen atrial muscle fibrillation tedisamil acts restore normal electrical rhythm heart prolonging inactivation phase muscle atrial ventricular repolarization lengthened tedisamil blocking multiple potassium channels including transient outward ito adenosine triphosphatedependent ikatp delayed rectifier potassium currents ikr tedisamil action dose dependent currents blocked longer effectively higher tedisamil activity greatest ito acts binding channel open produces blocked state delays restore normal function tedisamil must unbind channel inactivate eventually similar mechanisms observed ikr iks ito delayed rectifier channels tedisamil binding site appears internal binding unbinding occur effectively tedisamil applied inside tedisamil also appears provide specific single channel blocking ikatp high potassium channels responsible restoring resting membrane potential action potential lengthening inactivation stop cycle fibrillation preventing muscle contraction ion channels available open regular use tedisamil prevent fibrillation restore normal electrical rhythm tedisamil antiarrythmic activity also appears supported inhibiting sodium currents cardiac however observed concentrations concentrations higher required potassium channel httpsenwikipediaorgwikitedisamil